Balyasny Asset Management
HUMA icon

Balyasny Asset Management’s Humacyte HUMA Stock Holding History

Balyasny Asset Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.9K Buy
+21,610
New +$20K ﹤0.01% 2928
2022
Q2 		– Sell
-17,272
Closed -$122K – 2928
2022
Q1 		$122K Buy
+17,272
New +$101K ﹤0.01% 2112

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Balyasny Asset Management's HUMA Position: Q2 2026 in Review

Balyasny Asset Management opened a new position in Humacyte (HUMA) in Q2 2026: 21,610 shares worth $16.9K. The stake represents ﹤0.01% of the portfolio and ranks #2928 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in HUMA as recently as Q1 2022.

Balyasny Asset Management first reported a position in HUMA in Q1 2022 and has held it in 2 quarters since. The position peaked at $122K in Q1 2022. 164 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Balyasny Asset Management held 21,610 shares of Humacyte worth $16.9K as of Q2 2026.
  • Humacyte was a new Balyasny Asset Management position in Q2 2026.
  • Humacyte made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2928 holding.
  • Balyasny Asset Management first reported a position in Humacyte in Q1 2022 and has held it in 2 quarters since.
  • Balyasny Asset Management's Humacyte position peaked at $122K in Q1 2022.
  • 164 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.